| Literature DB >> 35600153 |
Agnieszka Turczyn1, Grażyna Krzemień1, Elżbieta Górska2, Urszula Demkow2, Małgorzata Pańczyk-Tomaszewska1.
Abstract
Congenital obstructive nephropathy (CON) is one of the most common causes of chronic kidney disease in children. The aim of the study was to investigate serum and urine periostin and cytokeratin-18 (CK-18) in children with CON in relation to CON etiology, treatment, and kidney injury. We evaluated 81 children with CON secondary to ureteropelvic junction obstruction (UPJO), ureterovesical junction obstruction (UVJO), posterior urethral valves (PUV) and 60 controls. Neither biomarker demonstrated any relation to CON etiology. However, all patients showed significantly higher urine periostin (uPeriostin) and uPeriostin/Cr levels than the controls. Also, UVJO patients showed higher sCK-18 and uCK-18/Cr levels, and PUV patients showed higher uCK-18/Cr levels than the controls. Neither biomarker was found to have any relation to CON treatment. However, conservatively treated children and those before and after surgery showed significantly higher uPeriostin and uPeriostin/Cr levels than the controls. uPeriostin strongly correlated with differential renal function (DRF) < 40%. The ROC analysis demonstrated the best area under the curve (AUC) for uPeriostin (0.831) and uPeriostin/Cr (0.768), and low for sPeriostin (0.656) and uCK-18 (0.615) for detecting renal injury. In conclusion, although serum and urine periostin and CK-18 did not display any relation to etiology or the type of CON treatment, uPeriostin seems to be a useful tool for detecting renal injury in children with CON, especially due to its strong negative correlation with DRF < 40%.Entities:
Keywords: children; congenital obstructive nephropathy; cytokeratin-18; periostin
Year: 2022 PMID: 35600153 PMCID: PMC9115600 DOI: 10.5114/ceji.2022.115687
Source DB: PubMed Journal: Cent Eur J Immunol ISSN: 1426-3912 Impact factor: 1.634
Fig. 1Flow diagram
Demographic and clinical data of the study groups and the control group
| Variables | Etiology of CON | Controls | |||||
|---|---|---|---|---|---|---|---|
| UPJO | UVJO | PUV | Total | ||||
| No. patients, | 53 (65) | 17 (21) | 11 (14) | 81 (100) | 60 (100) | ||
| Sex (male), | 38 (72) | 9 (53) | 11 (100) | 58 (72) | 39 (65) | ||
| Age at diagnosis (years) | 0.81 (0.10; 6.01) | 0.28 (0.11; 0.49) | 0.47 (0.06; 2.68) | 0.40 (0.10; 4.98) | – | ||
| Age at study entry (years) | 4.83 (0.92; 10.25) | 0.92 (0.58; 1.33) | 6.58 (1.08; 10.88) | 3.92 (0.67; 9.17) | 4.08 (1.83; 10.08) | ||
| Ultrasonography, | |||||||
| APD of renal pelvis | |||||||
| < 15 mm | 24 (45) | 15 (88) | 11 (100) | 50 (62) | – | ||
| 15-25 mm | 19 (36) | 2 (12) | 0 (0) | 21 (26) | |||
| > 25 mm | 10 (19) | 0 (0) | 0 (0) | 10 (12) | |||
| Renal scintigraphy, | |||||||
| DRF < 40% | 13 (25) | 2 (12) | 4 (36) | 19 (24) | – | ||
| DFR ≥ 40% | 40 (75) | 15 (88) | 7 (64) | 62 (76) | |||
| T1/2 tracer excretion | |||||||
| ≤ 20 min | 20 (38) | 11 (65) | 8 (73) | 39 (48) | |||
| > 20 min | 33 (62) | 6 (35) | 3 (27) | 42 (52) | |||
| Treatment, | – | ||||||
| Conservative | 35 (66) | 13 (76) | 0 (0) | 48 (59) | |||
| Before surgery | 13 (25) | 3 (18) | 3 (27) | 19 (24) | |||
| After surgery | 5 (9) | 1 (6) | 8 (73) | 14 (17) | |||
CON – congenital obstructive nephropathy, UPJO – ureteropelvic junction obstruction, UVJO – ureterovesical junction obstruction, PUV – posterior urethral valves, APD – anterior-posterior diameter, DRF – differential renal function of affected kidney, T1/2 – half-time of tracer excretion
Comparison of biomarkers between children with different etiology of CON and the controls. A. Comparison of biomarkers in children with UPJO and the controls. B. Comparison of biomarkers in children with UVJO and the controls. C. Comparison of biomarkers in children with PUV and the controls
| A. Variables | UPJO ( | Controls ( |
|
|---|---|---|---|
| sPeriostin (ng/ml) | 13435 ± 4410 | 16344 ± 7699 | 0.008 |
| uPeriostin (ng/ml) | 0.088 (0.062; 0.149) | 0.028 (0.013; 0.052) | < 0.001 |
| uPeriostin/Cr (ng/mg) | 0.208 (0.120; 0.459) | 0.081 (0.024; 0.164) | < 0.001 |
| sCK-18 (ng/ml) | 1.79 (1.28; 8.83) | 1.62 (1.38; 6.01) | 0.546 |
| uCK-18 (ng/ml) | 0.373 ± 0.153 | 0.320 ± 0.162 | 0.082 |
| uCK-18/Cr (ng/mg) | 0.686 (0.291; 1.64) | 0.562 (0.293; 1.580) | 0.406 |
|
|
|
|
|
| sPeriostin (ng/ml) | 15568 ± 3851 | 16344 ± 7699 | 0.577 |
| uPeriostin (ng/ml) | 0.098 (0.053; 0.132) | 0.028 (0.013; 0.052) | < 0.001 |
| uPeriostin/Cr (ng/mg) | 0.443 (0.180; 0.587) | 0.081 (0.024; 0.164) | < 0.001 |
| sCK-18 (ng/ml) | 3.89 (1.840; 25.08) | 1.62 (1.380; 6.01) | 0.041 |
| uCK-18 (ng/ml) | 0.379 ± 0.127 | 0.320 ± 0.162 | 0.172 |
| uCK-18/Cr (ng/mg) | 1.78 (0.880; 2.39) | 0.562 (0.293; 1.580) | 0.024 |
|
|
|
|
|
| sPeriostin (ng/ml) | 13361 ± 3638 | 16344 ± 7699 | 0.162 |
| uPeriostin (ng/ml) | 0.140 (0.075; 0.190) | 0.028 (0.013; 0.052) | < 0.001 |
| uPeriostin/Cr (ng/mg) | 0.287 (0.083; 0.397) | 0.081 (0.024; 0.164) | 0.016 |
| sCK-18 (ng/ml) | 2.30 (1.15; 118.65) | 1.62 (1.38; 6.01) | 0.540 |
| uCK-18 (ng/ml) | 0.440 ± 0.182 | 0.320 ± 0.162 | 0.031 |
| uCK-18/Cr (ng/mg) | 0.783 (0.328; 1.840) | 0.562 (0.293; 1.580) | 0.824 |
CON – congenital obstructive nephropathy, UPJO – ureteropelvic junction obstruction, UVJO – ureterovesical junction obstruction, PUV – posterior urethral valves, s – serum, u – urine, Cr – urine creatinine, CK-18 – cytokeratin-18
Fig. 2Comparison of biomarkers in children with UPJO, UVJO, PUV, and the controls: A) serum periostin, B) urine periostin, C) urine periostin/creatinine ratio
Comparison of biomarkers between children with different types of CON treatment and the controls. A. Comparison of biomarkers between children treated conservatively and the controls. B. Comparison of biomarkers between children before surgery and the controls. C. Comparison of biomarkers between children after surgery and the controls
| A. Variables | Conservative treatment ( | Controls ( |
|
|---|---|---|---|
| sPeriostin (ng/ml) | 14122 ± 4448 | 16344 ± 7699 | 0.053 |
| uPeriostin (ng/ml) | 0.086 (0.055; 0.141) | 0.028 (0.013; 0.052) | < 0.001 |
| uPeriostin/Cr (ng/mg) | 0.263 (0.124; 0.511) | 0.081 (0.024; 0.164) | < 0.001 |
| sCK-18 (ng/ml) | 1.94 (1.38; 21.60) | 1.62 (1.38; 6.01) | 0.416 |
| uCK-18 (ng/ml) | 0.369 ± 0.148 | 0.320 ± 0.162 | 0.107 |
| uCK-18/Cr (ng/mg) | 0.826 (0.292; 2.13) | 0.562 (0.293; 1.580) | 0.402 |
|
|
|
|
|
| sPeriostin (ng/ml) | 14844 ± 4231 | 16344 ± 7699 | 0.197 |
| uPeriostin (ng/ml) | 0.093 (0.080; 0.192) | 0.028 (0.013; 0.052) | < 0.001 |
| uPeriostin/Cr (ng/mg) | 0.331 (0.162; 0.591) | 0.081 (0.024; 0.164) | < 0.001 |
| sCK-18 (ng/ml) | 1.77 (1.09; 33.83) | 1.62 (1.38; 6.01) | 0.415 |
| uCK-18 (ng/ml) | 0.399 ± 0.166 | 0.320 ± 0.162 | 0.064 |
| uCK-18/Cr (ng/mg) | 1.40 (0.508; 2.41) | 0.562 (0.293; 1.580) | 0.105 |
|
|
|
|
|
| sPeriostin (ng/ml) | 11701 ± 2829 | 16344 ± 7699 | 0.030 |
| uPeriostin (ng/ml) | 0.133 (0.078; 0.208) | 0.028 (0.013; 0.052) | < 0.001 |
| uPeriostin/Cr (ng/mg) | 0.158 (0.100; 0.287) | 0.081 (0.024; 0.164) | 0.008 |
| sCK-18 (ng/ml) | 2.73 (1.15; 70.80) | 1.62 (1.38; 6.01) | 0.140 |
| uCK-18 (ng/ml) | 0.409 ± 0.154 | 0.320 ± 0.162 | 0.077 |
| uCK-18/Cr (ng/mg) | 0.589 (0.274; 0.897) | 0.562 (0.293; 1.580) | 0.756 |
CON – congenital obstructive nephropathy, s – serum, u – urine, Cr – urine creatinine, CK-18 – cytokeratin-18
Fig. 3Comparison of biomarkers in children with a different type of CON treatment and the controls A) urine periostin, B) urine periostin/Cr ratio
Diagnostic usefulness of biomarkers for detecting renal injury in children with obstructive nephropathy
| Variable | AUC (95% CI) |
| Cut-off | Sensitivity (%) | Specificity (%) | Accuracy (%) |
|---|---|---|---|---|---|---|
| sPeriostin (ng/ml) | 0.656 (0.563-0.748) | 0.001 | 14.939 | 64.2 | 67.8 | 65.7 |
| uPeriostin (ng/ml) | 0.831 (0.762-0.900) | < 0.001 | 0.062 | 75.3 | 80.0 | 77.3 |
| uPeriostin/Cr (ng/mg) | 0.768 (0.688-0.855) | < 0.001 | 0.120 | 77.8 | 70.0 | 73.8 |
| sCK-18 (ng/ml) | 0.564 (0.469-0.659) | 0.185 | 26.14 | 23.5 | 98.3 | 55.3 |
| uCK-18 (ng/ml) | 0.615 (0.519-0.710) | 0.019 | 0.272 | 80.2 | 43.3 | 61.9 |
| uCK-18/Cr (ng/mg) | 0.557 (0.482-0.672) | 0.114 | 0.666 | 58.0 | 58.3 | 58.2 |
s – serum, u – urine, Cr – urine creatinine, CK-18 – cytokeratin-18
Fig. 4Diagnostic usefulness of biomarkers for detecting renal injury in children with obstructive nephropathy A) serum periostin (ng/ml), B) urine periostin (ng/ml), C) urine periostin/Cr (ng/mg), D) urine cytokeratin-18 (ng/ml)
Correlations of serum periostin and cytokeratin-18 with other biomarkers in the study group and the control group
| Variable | Study group | Control group | ||||||
|---|---|---|---|---|---|---|---|---|
| sPeriostin | sCK-18 | sPeriostin | sCK-18 | |||||
| r | p | r | p | r | p | r | p | |
| sPeriostin | – | – | 0.02 | 0.874 | – | – | 0.11 | 0.425 |
| uPeriostin | –0.03 | 0.802 | –0.12 | 0.289 | 0.45 | < 0.001 | –0.05 | 0.683 |
| uPeriostin/Cr | 0.60 | < 0.001 | 0.06 | 0.596 | –0.09 | 0.515 | 0.08 | 0.543 |
| sCK-18 | 0.02 | 0.874 | – | – | 0.11 | 0.425 | – | – |
| uCK-18 | 0.14 | 0.221 | 0.22 | 0.046 | 0.02 | 0.855 | 0.17 | 0.182 |
| uCK-18/Cr | 0.53 | < 0.001 | 0.30 | 0.008 | 0.10 | 0.436 | 0.31 | 0.016 |
s – serum, u – urine, Cr – urine creatinine, CK-18 – cytokeratin-18
Fig. 5Correlations between age and biomarkers in the study group A) serum periostin, B) urine periostin/Cr, C) urine cytokeratin-18/Cr